{
    "ticker": "SGMO",
    "name": "Sangamo Therapeutics, Inc.",
    "description": "Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic therapies to treat a range of diseases. Founded in 1995 and headquartered in Richmond, California, the company specializes in gene editing, gene therapy, and cell therapy technologies. Sangamo's proprietary platform utilizes zinc finger protein (ZFP) technology to precisely edit genes and modulate gene expression. This innovative approach aims to address genetic disorders, hemophilia, and other serious diseases by providing targeted treatments that can potentially cure or significantly improve patient outcomes. The company's lead programs include treatments for hemophilia A and B, lysosomal storage disorders, and various types of cancer. With a strong commitment to advancing the field of genomic medicine, Sangamo collaborates with leading pharmaceutical companies and academic institutions to bring its groundbreaking therapies to the clinic. As the demand for personalized medicine grows, Sangamo is positioning itself as a leader in the biopharmaceutical sector, making significant strides in the development of next-generation therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Richmond, California, USA",
    "founded": "1995",
    "website": "https://www.sangamo.com",
    "ceo": "Sandy Macrae",
    "social_media": {
        "twitter": "https://twitter.com/SangamoTx",
        "linkedin": "https://www.linkedin.com/company/sangamo-therapeutics/"
    },
    "investor_relations": "https://investors.sangamo.com",
    "key_executives": [
        {
            "name": "Sandy Macrae",
            "position": "CEO"
        },
        {
            "name": "J. David E. Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Editing",
            "products": [
                "ZFP Technology"
            ]
        },
        {
            "category": "Gene Therapy",
            "products": [
                "Hemophilia Treatments"
            ]
        },
        {
            "category": "Cell Therapy",
            "products": [
                "Cancer Treatments"
            ]
        }
    ],
    "seo": {
        "meta_title": "Sangamo Therapeutics, Inc. | Gene Editing and Therapy Solutions",
        "meta_description": "Explore Sangamo Therapeutics, a leader in genomic medicine focused on developing innovative therapies for genetic disorders and serious diseases through gene editing and gene therapy.",
        "keywords": [
            "Sangamo",
            "Gene Editing",
            "Gene Therapy",
            "Zinc Finger Technology",
            "Hemophilia",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is Sangamo Therapeutics known for?",
            "answer": "Sangamo Therapeutics is known for its innovative approaches to gene editing and gene therapy, focusing on treating serious genetic disorders."
        },
        {
            "question": "Who is the CEO of Sangamo Therapeutics?",
            "answer": "Sandy Macrae is the CEO of Sangamo Therapeutics, Inc."
        },
        {
            "question": "Where is Sangamo headquartered?",
            "answer": "Sangamo is headquartered in Richmond, California, USA."
        },
        {
            "question": "What are Sangamo's main products?",
            "answer": "Sangamo's main products include gene editing technologies and therapies for hemophilia and cancer."
        },
        {
            "question": "When was Sangamo founded?",
            "answer": "Sangamo was founded in 1995."
        }
    ],
    "competitors": [
        "EDIT",
        "CRSP",
        "NTLA"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "BIIB",
        "GILD"
    ]
}